Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.43 |
| ▸ | KRAS | P01116 | 3/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | ARAF | P10398 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.43 |
| ▸ | CSK | P41240 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.43 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22625605 | 0.91 | RAF1 (0.49) | RAF1KRASBRAFKDRMAPK13 | |
| SCHEMBL22652926 | 0.89 | ALDH1A1 (0.42) | RAF1KRASBRAFKDRMAPK14 | |
| SCHEMBL22625543 | 0.85 | BRAF (0.60) | RAF1KRASBRAFKDRMAPK13 | |
| SCHEMBL22652928 | 0.81 | KDR (0.44) | RAF1KRASBRAFKDRABL1 | |
| SCHEMBL24367126 | 0.75 | ALDH1A1 (0.55) | ALDH1A1RAB9ATSHRSMN1; SMN2BTK | |
| SCHEMBL22625561 | 0.75 | KDR (0.59) | RAF1KRASBRAFKDRMAPK13 | |
| SCHEMBL22625600 | 0.73 | ALDH1A1 (0.37) | ALDH1A1RAB9ATSHRSMN1; SMN2BTK | |
| SCHEMBL22612961 | 0.71 | LCK (0.60) | RAF1BRAFKDRMAPK14JAK3 | |
| SCHEMBL22625562 | 0.70 | RAF1 (0.44) | RAF1KRASBRAFKDRMAPK13 | |
| SCHEMBL25322394 | 0.67 | ALDH1A1 (0.41) | ALDH1A1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
| US-10927111-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| WO-2020227020-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | RAF1 2/4885KRAS 5/4885BRAF 1/4885 |
| US-11667634-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | RAF1 2/4885KRAS 5/4885BRAF 1/4885 |
| US-10927111-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | RAF1 2/4885KRAS 5/4885BRAF 1/4885 |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | RAF1 2/4885KRAS 5/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.